Citadel Advisors
KRTX

Citadel Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Citadel Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-49,400
Closed -$15.6M – 15741
2023
Q4 		$15.6M Buy
49,400
+13,800
+39% +$2.68M ﹤0.01% 2283
2023
Q3 		$6.02M Buy
35,600
+20,200
+131% +$3.8M ﹤0.01% 3367
2023
Q2 		$3.34M Sell
15,400
-5,200
-25% -$1.11M ﹤0.01% 4283
2023
Q1 		$3.74M Sell
20,600
-10,500
-34% -$2.01M ﹤0.01% 4292
2022
Q4 		$6.11M Buy
31,100
+10,600
+52% +$2.27M ﹤0.01% 3537
2022
Q3 		$4.61M Buy
20,500
+4,000
+24% +$810K ﹤0.01% 4010
2022
Q2 		$2.09M Buy
16,500
+5,200
+46% +$598K ﹤0.01% 5460
2022
Q1 		$1.43M Buy
11,300
+7,800
+223% +$878K ﹤0.01% 6846
2021
Q4 		$459K Buy
3,500
+800
+30% +$103K ﹤0.01% 9908
2021
Q3 		$330K Sell
2,700
-4,100
-60% -$473K ﹤0.01% 10862
2021
Q2 		$775K Sell
6,800
-6,300
-48% -$736K ﹤0.01% 9029
2021
Q1 		$1.57M Buy
13,100
+4,700
+56% +$532K ﹤0.01% 6987
2020
Q4 		$853K Buy
8,400
+3,100
+58% +$287K ﹤0.01% 7129
2020
Q3 		$410K Sell
5,300
-600
-10% -$51.1K ﹤0.01% 7621
2020
Q2 		$658K Sell
5,900
-5,700
-49% -$496K ﹤0.01% 6579
2020
Q1 		$835K Buy
+11,600
New +$992K ﹤0.01% 5646

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Citadel Advisors's KRTX Position: Q1 2024 in Review

Citadel Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 158,012 shares — an estimated $50M sold.

Citadel Advisors first reported a position in KRTX in Q2 2019 and held it in 17 quarters. The position peaked at $50M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Citadel Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 158,012 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $50M.
  • Citadel Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 17 quarters.
  • Citadel Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $50M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.